Potential utility of HOP homeobox gene promoter methylation as a marker of tumor aggressiveness in gastric cancer

Oncogene

Volumn 29, Issue 22, 2010, Pages 3263-3275

  Ooki, A ^a   Yamashita, K ^a   Kikuchi, S ^a   Sakuramoto, S ^a   Katada, N ^a   Kokubo, K ^b   Kobayashi, H ^b   Kim, M S ^c   Sidransky, D ^c   Watanabe, M ^a  

^a KITASATO UNIVERSITY HOSPITAL   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Gastric cancer; HOP homeobox; Methylation; Prognosis

Indexed keywords

ADVANCED CANCER; ARTICLE; CONTROLLED STUDY; GENE SEQUENCE; GENE SILENCING; HOMEOBOX; HOP HOMEOBOX; HUMAN; HUMAN CELL; HUMAN TISSUE; METHYLATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; QUANTITATIVE METHYLATION SPECIFIC POLYMERASE CHAIN REACTION; STOMACH CANCER; CELL GROWTH; COHORT ANALYSIS; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE; TUMOR INVASION;

CELL GROWTH PROCESSES; CELL LINE, TUMOR; COHORT STUDIES; CPG ISLANDS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, HOMEOBOX; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; PROGNOSIS; PROMOTER REGIONS, GENETIC; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

HOMEODOMAIN PROTEIN; HOP PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

EID: 77953230271     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.76     Document Type: Article

References (39)

1. Brena RM, Huang TH, Plass C. (2006). Quantitative assessment of DNA methylation: potential applications for disease diagnosis, classification, and prognosis in clinical settings. J Mol Med 84: 365-377.
2. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. (1999). Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103-107.
3. Chen F, Kook H, Milewski R, Gitler AD, Lu MM, Li J et al. (2002). Hop is an unusual homeobox gene that modulates cardiac development. Cell 110: 713-723.
4. Chen Y, Pacyna-Gengelbach M, Deutschmann N, Niesporek S, Petersen I. (2007). Homeobox gene HOP has a potential tumor suppressive activity in human lung cancer. Int J Cancer 121: 1021-1027.
5. Crew KD, Neugut AI. (2006). Epidemiology of gastric cancer. World J Gastroenterol 12: 354-362.
6. Esteller M. (2003). Relevance of DNA methylation in the management of cancer. Lancet Oncol 4: 351-358. (Pubitemid 36748422)
7. Japanese Gastric Cancer Association (1998). Japanese Classification of Gastric Carcinoma. 2nd English edn Gastric Cancer 1: 10-24.
8. Kee HJ, Kim JR, Nam KI, Park HY, Shin S, Kim JC et al. (2007). Enhancer of polycomb1, a novel homeodomain only protein-binding partner, induces skeletal muscle differentiation. J Biol Chem 282: 7700-7709.
9. Kook H, Yung WW, Simpson RJ, Kee HJ, Shin S, Lowry JA et al. (2006). Analysis of the structure and function of the transcriptional coregulator HOP. Biochemistry 45: 10584-10590.
10. Laird PW. (2003). The power and the promise of DNA methylation markers. Nat Rev Cancer 3: 253-266.
11. Lehnert T, Rudek B, Kienle P, Buhl K, Herfarth C. (2002). Impact of diagnostic laparoscopy on the management of gastric cancer: prospective study of 120 consecutive patients with primary gastric adenocarcinoma. Br J Surg 89: 471-475.
12. Liu JW, Kim MS, Nagpal J, Yamashita K, Poeta L, Chang X et al. (2007). Quantitative hypermethylation of NMDAR2B in human gastric cancer. Int J Cancer 121: 1994-2000.
13. Livak KJ, Schmittgen TD. (2001). Analysis of relative gene expression data using real-time quantitaitve PCR and the 2(-Delta Delata C(T)) method. Methods 25: 402-408.
14. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. (1999). Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 229: 303-308.
15. Mandelker DL, Yamashita K, Tokumaru Y, Mimori K, Howard DL, Tanaka Y et al. (2005). PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 65: 4963-4968.
16. Miotto E, Sabbioni S, Veronese A, Calin GA, Gullini S, Liboni A et al. (2004). Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. Cancer Res 64: 8156-8159.
17. Nakajima T. (2002). Gastric cancer treatment guidelines in Japan. Gastric Cancer 5: 1-5.
18. Nishihira T, Hashimoto Y, Katayama M. (1993). Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol 119: 441-449.
19. Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Watanabe M. (2009). Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma. Int J Cancer (in press).
20. Oshimo Y, Oue N, Mitani Y, Nakayama H, Kitadai Y, Yoshida K et al. (2004a). Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma. Pathobiology 71: 137-143. (Pubitemid 38437708)
21. Oshimo Y, Oue N, Mitani Y, Nakayama H, Kitadai Y, Yoshida K et al. (2004b). Frequent epigenetic inactivation of RIZ1 by promoter hypermethylation in human gastric carcinoma. Int J Cancer 110: 212-218. (Pubitemid 38580393)
22. Park J, Song SH, Kim TY, Choi MC, Jong HS, Lee JW et al. (2004). Aberrant methylation of integrin alpha4 gene in human gastric cancer cells. Oncogene 23: 3474-3480.
23. Remmele W, Schicketanz KH. (1993). Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs subjective grading (IRS). Pathol Res Pract 189: 862-866.
24. Remmele W, Stegner HE. (1987). Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochem-ical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140.
25. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A et al. (2007). Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357: 1810-1820.
26. Sotiriou C, Piccart MJ. (2007). Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 7: 545-553.
27. Takahashi T, Suzuki M, Shigematsu H, Shivapurkar N, Echebiri C, Nomura M et al. (2005). Aberrant methylation of Reprimo in human malignancies. Int J Cancer 115: 503-510. (Pubitemid 40656706)
28. Tokumaru Y, Nomoto S, Jeronimo C, Henrique R, Harden S, Trink B et al. (2003). Biallelic inactivation of the RIZ1 gene in human gastric cancer. Oncogene 22: 6954-6958.
29. Tokumaru Y, Yamashita K, Kim MS, Park HL, Osada M, Mori M, et al. (2008). The role of PGP9.5 as a tumor suppressor gene in human cancer. Int J Cancer 123: 753-759.
30. Tomii K, Tsukuda K, Toyooka S, Dote H, Hanafusa T, Asano H, et al. (2007). Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers. Int J Cancer 120: 566-573.
31. Ushijima T. (2007). Epigenetic field for cancerization. J Biochem Mol Biol 40: 142-150.
32. Waki T, Tamura G, Sato M, Terashima M, Nishizuka S, Motoyama T. (2003). Promoter methylation status of DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric epithelia. Cancer Sci 94: 360-364.
33. Wei D, Gong W, Kanai M, Schlunk C, Wang L, Yao JC et al. (2005) Drastic down-regulation of Kruppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res 65: 2746-2754.
34. Yamaguchi S, Asanoma K, Takao T, Kato K, Wake N. (2009) Homeobox gene HOPX is epigenetically silenced in human uterine endometrial cancer and suppresses estrogen-stimulated proliferation of cancer cells by inhibiting serum response factor. Int J Cancer 124: 2577-2588.
35. Yamashita K, Kim MS, Park HL, Tokumaru Y, Osada M, Inoue H et al. (2008). HOP/OB1/NECC1 promoter DNA is frequently hypermethylated and involved in tumorigenic ability in esophageal squamous cell carcinoma. Mol Cancer Res 6: 31-41.
36. Yamashita K, Park HL, Kim MS, Osada M, Tokumaru Y, Inoue H et al. (2006). PGP9.5 methylation in diffuse-type gastric cancer Cancer Res 66: 3921-3927.
37. Yamashita K, Watanabe M. (2009). Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci 100: 195-199.
38. Zhang YJ, Fang JY. (2008). Molecular staging of gastric cancer J Gastroenterol Hepatol 23: 856-860.
39. Zou B, Chim CS, Zeng H, Leung SY, Yang Y, Tu SP et al. (2006) Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers Gastroenterology 131: 1835-1843.